Compare medicines

Pick two or three products and see them side by side. The first view compares the two newer weight-loss pills.

Read this first. Trial figures come from different studies with different people, lengths and designs, so they are not head-to-head results. Head-to-head trials are labeled as such where the Atlas has added them (for example SURMOUNT-5 and STEP 8). Many have not been added yet, even where such trials exist.

First medicine

Second medicine

Third medicine (optional)

Compared item	Semaglutide injection (Wegovy)	Oral semaglutide for weight management (Wegovy pill)	Tirzepatide injection (Zepbound)	Orforglipron tablets (Foundayo)	Retatrutide injection (investigational)	CagriSema injection (under FDA review)	Liraglutide injection (Saxenda)	Phentermine and topiramate extended-release capsules (Qsymia)	Naltrexone and bupropion extended-release tablets (Contrave)	Orlistat 120 mg capsules (Xenical)	Phentermine hydrochloride tablets (Lomaira and other brands)	Diethylpropion hydrochloride tablets (generic)	Setmelanotide injection (Imcivree)	Pramlintide injection (Symlin)	Survodutide injection (investigational)	Mazdutide injection (approved in China, investigational in the U.S.)	Cagrilintide injection (investigational as a stand-alone medicine)	Eloralintide injection (investigational)	Petrelintide injection (investigational)	Zenagamtide injection (investigational)	Zenagamtide tablet (investigational)	VK2735 injection (investigational)	VK2735 tablet (investigational)	Maridebart cafraglutide injection (investigational)	Pemvidutide injection (investigational)
Generic name	Semaglutide	Semaglutide	Tirzepatide	Orforglipron	Retatrutide	CagriSema	Liraglutide	Phentermine and topiramate	Naltrexone and bupropion	Orlistat	Phentermine	Diethylpropion	Setmelanotide	Pramlintide	Survodutide	Mazdutide	Cagrilintide	Eloralintide	Petrelintide	Zenagamtide	Zenagamtide	VK2735	VK2735	Maridebart cafraglutide	Pemvidutide
Brand names	Wegovy (weight management), Wegovy HD (weight management), Ozempic (type 2 diabetes)	Wegovy pill (weight management), Rybelsus (type 2 diabetes)	Zepbound (weight management), Mounjaro (type 2 diabetes)	Foundayo (weight management)	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.	Saxenda (weight management), Victoza (type 2 diabetes)	Qsymia (weight management)	Contrave (weight management)	Xenical, Alli (no separate brand page yet)	Lomaira, Adipex-P (no separate brand page yet)	Tenuate (no separate brand page yet)	Imcivree (no separate brand page yet)	Symlin (no separate brand page yet)	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.	No brand name recorded. Not approved in the U.S.
Medicine class	GLP-1 receptor agonist	GLP-1 receptor agonist	GIP and GLP-1 receptor agonist	GLP-1 receptor agonist (non-peptide pill)	GIP, GLP-1 and glucagon receptor agonist	Amylin analog plus GLP-1 receptor agonist	GLP-1 receptor agonist	Appetite suppressant plus anticonvulsant combination	Opioid antagonist plus antidepressant combination	Lipase inhibitor	Sympathomimetic appetite suppressant	Sympathomimetic appetite suppressant	Melanocortin-4 receptor agonist	Amylin analog	GLP-1 and glucagon receptor agonist	GLP-1 and glucagon receptor agonist	Amylin receptor agonist	Amylin receptor agonist	Amylin receptor agonist	GLP-1 and amylin receptor agonist	GLP-1 and amylin receptor agonist	GIP and GLP-1 receptor agonist	GIP and GLP-1 receptor agonist	GIP receptor antagonist antibody linked to GLP-1 agonist peptides	GLP-1 and glucagon receptor agonist
Targets	GLP-1	GLP-1	GIP, GLP-1	GLP-1	GIP, GLP-1, Glucagon	Amylin, GLP-1	GLP-1	Other	Other	Other	Other	Other	MC4R	Amylin	GLP-1, Glucagon	GLP-1, Glucagon	Amylin	Amylin	Amylin	GLP-1, Amylin	GLP-1, Amylin	GIP, GLP-1	GIP, GLP-1	GIP, GLP-1	GLP-1, Glucagon
How it is taken	Once weekly. Weekly injection. Follow the label and your prescriber for how to use it.	Once daily. Per the label, the tablet is taken once a day in the morning on an empty stomach, with plain water (up to 4 ounces), and swallowed whole. The label says to wait at least 30 minutes before eating, drinking anything else or taking other oral medicines.	Once weekly. Weekly injection. Follow the label and your prescriber for how to use it.	Once daily. Per the label, the tablet is taken once a day, with or without food, and swallowed whole. The label says not to break, crush or chew it.	Once weekly in trials. Only available inside clinical trials or a sponsor-run expanded-access program. Anything else sold under this name is not a regulated medicine.	Once weekly in trials. Weekly injection used in trials only. It is not available as an approved product.	Once daily. Daily injection under the skin from a prefilled pen. Follow the label and your prescriber for how to use it.	Once daily. Daily capsule. Follow the label and your prescriber. It is not for use in pregnancy, and pregnancy tests are recommended before starting and monthly during treatment.	Daily, with a gradual build-up over several weeks. Daily tablet with a gradual build-up. Follow the label and your prescriber. Tell the prescriber about any opioid, seizure or mental-health history first.	With meals, up to three times a day. Taken with meals that contain fat. A daily multivitamin is advised by the label. Follow the label and your prescriber.	Daily, as set by the prescriber. Short-term use only, per the label. It should not be combined with other weight-loss drugs.	Three times daily before meals on the immediate-release label. Short-term use only, per the label. It should not be combined with other weight-loss drugs.	Once daily. Used only for the specific conditions on the label. It is not a treatment for common obesity.	Injected under the skin before each major meal, per the label. For diabetes only, with mealtime insulin. The label cuts the mealtime insulin dose by half when starting.	Once weekly in trials. Available only inside clinical trials.	Once weekly in trials. Not available in the U.S. outside clinical trials.	Once weekly in trials. Available only inside clinical trials, or as part of CagriSema if that is approved.	Once weekly in trials. Available only inside clinical trials.	Once weekly in trials. Available only inside clinical trials.	Once weekly in trials. Available only inside clinical trials.	Once daily in trials. Available only inside clinical trials.	Once weekly in trials. Available only inside clinical trials.	Once daily in the phase 2 trial. Available only inside clinical trials.	Once monthly or less often in trials. Available only inside clinical trials.	Once weekly in trials. Available only inside clinical trials.
U.S. status	FDA-approved for weight management. Approved in the U.S. for weight reduction in adults with obesity, or overweight plus a weight-related condition, and in children 12 and older with obesity. Also approved to lower cardiovascular risk in some adults and to treat MASH with liver scarring. Used with diet and activity. A higher-strength injection, Wegovy HD, was approved in March 2026 for the same weight-reduction purpose.	FDA-approved for weight management. Approved in the U.S. for weight reduction in adults with obesity, or overweight plus a weight-related condition, and to lower cardiovascular risk in some adults. The tablet label does not include the injection's uses in children or for MASH. Used with diet and activity. Trade press dates the approval to December 2025.	FDA-approved for weight management. Approved in the U.S. for weight reduction in adults with obesity, or overweight plus a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. Used with diet and activity.	FDA-approved for weight management. Approved in the U.S. for weight reduction in adults with obesity, or overweight plus at least one weight-related condition. Used with diet and activity. Trade press dates the approval to April 1, 2026. Type 2 diabetes is not recorded as an approved use here.	Investigational. Not approved anywhere. Phase 3 obesity results are published (TRIUMPH-1 and TRIUMPH-2). Lilly stated on July 23, 2026 that it plans to submit retatrutide to the FDA in the first quarter of 2027. An expanded-access program is listed on ClinicalTrials.gov.	Under FDA review. Not approved. Novo Nordisk announced on December 18, 2025 that it had submitted a new drug application to the FDA, based on the REDEFINE 1 and REDEFINE 2 trials. No approval was recorded as of mid-October 2026. Novo Nordisk said only that the FDA was expected to review the application in 2026; some third-party trackers report a decision in the fourth quarter of 2026, but the company has not confirmed a date.	FDA-approved for weight management. Approved in the U.S. for weight management in adults with obesity, or overweight plus a weight-related condition, and in children 12 and older who weigh more than 60 kg and have obesity.	FDA-approved for weight management. Approved in the U.S. as an add-on to a reduced-calorie diet and more physical activity, to reduce excess weight and keep it off. For adults with obesity, adults with overweight plus a weight-related condition, and patients 12 and older with obesity. It is a Schedule IV controlled substance and is dispensed only through certified pharmacies under a pregnancy-risk program (REMS).	FDA-approved for weight management. Approved in the U.S. as an add-on to a reduced-calorie diet and more physical activity for long-term weight reduction in adults with obesity, or overweight plus at least one weight-related condition. Not approved for children.	FDA-approved for weight management. Approved in the U.S. for weight loss and weight maintenance with a reduced-calorie diet, and to reduce regain after weight loss, in adults with a BMI of 30 or more, or 27 or more with risk factors. Studied in adolescents 12 to 16. A lower-strength over-the-counter version (Alli) is sold separately.	FDA-approved for weight management. Approved in the U.S. as a short-term add-on to a reduced-calorie diet, exercise and behavior change for adults with obesity, or overweight plus risk factors such as controlled high blood pressure, diabetes or high cholesterol. Other brands and strengths, including Adipex-P, are also sold; only the Lomaira label was checked here. It is a Schedule IV controlled substance.	FDA-approved for weight management. Approved in the U.S. as a short-term add-on (a few weeks) to a reduced-calorie diet for adults with a BMI of 30 or more who have not responded to diet and exercise alone. It is approved as the only weight-loss medicine in use, not alongside others. It is a Schedule IV controlled substance. DailyMed lists immediate-release and extended-release tablets from several generic makers; only the immediate-release 25 mg label from KVK-Tech was read here.	FDA-approved for weight management. Approved in the U.S. (first in 2020) to reduce excess body weight and keep it off in people with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing (age 2 and older), Bardet-Biedl syndrome (age 2 and older), or acquired hypothalamic obesity (age 4 and older). It is not for common obesity.	FDA-approved, but not for obesity. Approved in the U.S. as an add-on for adults with type 1 or type 2 diabetes who use mealtime insulin and have not reached their blood sugar goals. It is not approved for obesity or weight loss. The label carries a boxed warning for severe low blood sugar.	Investigational. Not approved. Boehringer Ingelheim ran two phase 3 obesity trials (SYNCHRONIZE-1 and -2), both now published in the New England Journal of Medicine, plus a heart-outcomes trial the registry lists as completed. Separate trials in fatty liver disease are also listed. This atlas did not find a confirmed FDA filing.	Investigational. Not approved by the FDA. According to the company, China's regulator (NMPA) approved it for chronic weight management in adults in June 2025, and an application for type 2 diabetes in China was reported to be under review at that time. Approval status in other countries was not found.	Investigational. Not approved on its own. Cagrilintide is one component of CagriSema, which is under FDA review (see the CagriSema page). A phase 3 trial of cagrilintide alone in obesity with type 2 diabetes is listed as active.	Investigational. Not approved. Eli Lilly has started phase 3 trials: one in adults with obesity without type 2 diabetes (1,980 people), one in people whose weight has stayed high on a weekly incretin medicine (900 people), and one combining eloralintide with tirzepatide in type 2 diabetes that is not yet recruiting.	Investigational. Not approved. Hoffmann-La Roche is the registered sponsor of three phase 3 trials that started recruiting in September 2026: one in overweight or obesity (3,900 people), one with type 2 diabetes (600) and one with established cardiovascular disease (2,500).	Investigational. Not approved. Novo Nordisk's phase 3 program includes AMAZE 7, a trial against semaglutide in about 650 people that started in September 2026, plus other obesity and diabetes trials.	Investigational. Not approved. AMAZE 9, a phase 3 trial of the daily tablet in about 950 people with obesity, started in August 2026.	Investigational. Not approved. Viking Therapeutics is running two 78-week phase 3 trials of the injection, one in adults without type 2 diabetes (4,500 people) and one in adults with type 2 diabetes (1,100). Both are listed as no longer recruiting, with primary completion registered for July 2027. This atlas did not find a regulatory filing.	Investigational. Not approved. A 13-week phase 2 trial (280 people) is complete, and the company announced its results in August 2025. Two 68-week phase 3 tablet trials, one without and one with type 2 diabetes (560 people each), are registered as not yet recruiting, with a listed start of November 2026.	Investigational. Not approved. Amgen is running a phase 3 program called MARITIME. The main obesity trials (MARITIME-1 and MARITIME-2) are listed as active, with results not yet reported.	Investigational. Not approved. Altimmune began enrolling PERFORMA, a phase 3 trial in adults with MASH (about 1,790 people), in August 2026. The registry lists a primary completion date of December 2028. The company says it holds FDA Breakthrough Therapy and Fast Track designations for MASH. Phase 2 trials in alcohol use disorder (RECLAIM) and alcohol-associated liver disease (RESTORE) are also registered. This atlas found no phase 3 obesity trial.
Trial figures	STEP 1: −14.9% vs −2.4% placebo over 68 weeks. STEP 5: −15.2% vs −2.6% placebo over 104 weeks. STEP 8: semaglutide −15.8%, liraglutide −6.4% vs −1.9% placebo over 68 weeks. STEP UP: 7.2 mg −18.7%, 2.4 mg −15.6% vs −3.9% placebo over 72 weeks. These figures come from weight-management studies, not from the diabetes products.	OASIS 4: −13.6% vs −2.2% placebo over 64 weeks. These figures come from weight-management studies, not from the diabetes products.	SURMOUNT-1: −15.0%, −19.5%, −20.9% vs −3.1% placebo over 72 weeks. SURMOUNT-5: tirzepatide −20.2%, semaglutide −13.7% over 72 weeks, head to head. These figures come from weight-management studies, not from the diabetes products.	ATTAIN-1: −7.5%, −8.4%, −11.2% vs −2.1% placebo over 72 weeks.	Retatrutide phase 2 (obesity): −8.7%, −17.1%, −22.8%, −24.2% vs −2.1% placebo over 48 weeks. TRIUMPH-1: −17.6%, −23.7%, −25.0% vs −3.9% placebo over 80 weeks. TRIUMPH-2: −11.9%, −16.8%, −18.8% vs −5.1% placebo over 80 weeks.	REDEFINE 1: −20.4% vs −3.0% placebo over 68 weeks. REDEFINE 2: −13.7% vs −3.4% placebo over 68 weeks.	SCALE Obesity and Prediabetes: −8.4 kg vs −2.8 kg placebo over 56 weeks. These figures come from weight-management studies, not from the diabetes products.	CONQUER: −7.8%, −9.8% vs −1.2% placebo over 56 weeks.	COR-I: −5.0%, −6.1% vs −1.3% placebo over 56 weeks.	XENDOS: −5.8 kg vs −3.0 kg placebo over 208 weeks.	Low-dose phentermine before weight-loss surgery: −4.7% vs −1.1% placebo over 14 weeks.	Diethylpropion 12-month trial (Brazil): −9.8% vs −3.2% placebo over 26 weeks.	Setmelanotide in POMC and LEPR deficiency: POMC 80%, LEPR 45% reached the goal (at least 10% weight loss) over 52 weeks. There was no placebo group.	Pramlintide with phentermine (obesity): −3.7%, −11.3% vs −2.2% placebo over 24 weeks.	Survodutide phase 2 (obesity): −6.2%, −12.5%, −13.2%, −14.9% vs −2.8% placebo over 46 weeks. SYNCHRONIZE-1: −12.2%, −13.0% vs −5.4% placebo over 76 weeks. SYNCHRONIZE-2: −8.2%, −9.8% vs −3.9% placebo over 76 weeks.	GLORY-1: −11.0%, −14.0% vs +0.3% placebo over 48 weeks. GLORY-2: −16.6% vs −1.5% placebo over 60 weeks.	Cagrilintide phase 2 (obesity): −6.0%, −10.8%, −9.0% vs −3.0% placebo over 26 weeks.	Eloralintide phase 2 (obesity): −9.0%, −12.0%, −18.0%, −20.0% vs −0.4% placebo over 48 weeks.	ZUPREME-1 (petrelintide): −7.9%, −9.8%, −9.4% vs −1.7% placebo over 28 weeks.	Zenagamtide (amycretin) phase 1b/2a: −24.3%, −22.0% vs −1.1% placebo over 36 weeks.	No trial figures added to this atlas yet.	VENTURE (VK2735 injection): −9.1%, −14.7% vs −1.7% placebo over 13 weeks.	VENTURE-Oral (VK2735 tablet): −2.3%, −7.0%, −8.7%, −11.1%, −12.2% vs −1.3% placebo over 13 weeks.	MariTide phase 2 (obesity): −12.3%, −16.2% vs −2.5% placebo over 52 weeks.	MOMENTUM (pemvidutide, obesity): −10.3%, −11.2%, −15.6% vs −2.2% placebo over 48 weeks.

Ozempic, Mounjaro, Rybelsus and Victoza are approved for type 2 diabetes. They appear in the "Brand names" row but have no separate column because this atlas's weight-loss figures come from the weight-management products.